Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine

• Published in: The Journal of biological chemistry 2020-05, Vol.295 (21), p.7179-7192
• Main Authors: Center, Rob J., Boo, Irene, Phu, Lilian, McGregor, Joey, Poumbourios, Pantelis, Drummer, Heidi E.
• Format: Article
• Language: English
• Subjects: Amino Acid Substitution; Animals; Antibodies, Neutralizing - immunology; antigen engineering; broadly neutralizing antibody (bNAb); D123-HMW; disulfide; Editors' Picks; glycoprotein; Glycoproteins - genetics; Glycoproteins - immunology; Guinea Pigs; Hepacivirus - genetics; Hepacivirus - immunology; Hepatitis Antibodies - immunology; Hepatitis Antigens - genetics; Hepatitis Antigens - immunology; hepatitis C virus (HCV); Humans; immunogenicity; Immunogenicity, Vaccine; multimerization; Mutation, Missense; protein refolding; vaccine development; Viral Hepatitis Vaccines - genetics; Viral Hepatitis Vaccines - immunology; Viral Proteins - genetics; Viral Proteins - immunology
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA120.013015

The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly neutralizing antibodies (bNAbs) that are critical for the efficacy of a prophylactic HCV vaccine. We previously showed that a cell culture–derived, disulfide-linked high-molecular-weight (HMW) form of the E2 receptor–binding domain lacking three variable regions, Δ123-HMW, elicits broad neutralizing activity against the seven major genotypes of HCV. A limitation to the use of this antigen is that it is produced only at low yields and does not have a homogeneous composition. Here, we employed a sequential reduction and oxidation strategy to efficiently refold two high-yielding monomeric E2 species, D123 and a disulfide-minimized version (D123A7), into disulfide-linked HMW-like species (Δ123r and Δ123A7r). These proteins exhibited normal reactivity to bNAbs with continuous epitopes on the neutralizing face of E2, but reduced reactivity to conformation-dependent bNAbs and nonneutralizing antibodies (non-NAbs) compared with the corresponding monomeric species. Δ123r and Δ123A7r recapitulated the immunogenic properties of cell culture–derived D123-HMW in guinea pigs. The refolded antigens elicited antibodies that neutralized homologous and heterologous HCV genotypes, blocked the interaction between E2 and its cellular receptor CD81, and targeted the AS412, AS434, and AR3 domains. Of note, antibodies directed to epitopes overlapping with those of non-NAbs were absent. The approach to E2 antigen engineering outlined here provides an avenue for the development of preventive HCV vaccine candidates that induce bNAbs at higher yield and lower cost.